BACK TO HOME European Mid-Caps BACK TO HOME Pierre Fabre: Medicalization, Convergence & the Rise of ‘Onco-Dermatology’ Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million since 2014.…
BACK TO HOME European Mid-Caps BACK TO HOME European MidPharmas: Focused and Resilient, yet Vulnerable European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off…
BACK TO HOME European Mid-Caps BACK TO HOME Swiss Mid-Caps and Minnows: At the Vanguard of Creativity In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
HOMEPAGE European Mid-Caps European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta. Read more Servier’s…
BACK TO HOME Cell & Gene Therapy BACK TO HOME Emanuele Ostuni Head of cell & gene therapy for europe, novartis oncology Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe,…
BACK TO HOME Cell & Gene Therapy BACK TO HOME Big Pharma’s Quest for Blockbuster CAR-T It has been a full three years since, first Novartis, then Gilead, took the medical world by storm by gaining FDA approvals for chimeric antigen receptor (CAR) T-cell therapies, billed as…
BACK TO HOME Cell & Gene Therapy BACK TO HOME Cell & Gene Therapies Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable…
BACK TO HOME Cell & Gene Therapy BACK TO HOME Taking Cell & Gene Mainstream With the genomics revolution now entering full swing, expectations for the future of cell and gene therapy have never been higher. “Gene therapy, somatic-cell therapy and tissue engineering are actually all technologies…
BACK TO HOME Cell & Gene Therapy BACK TO HOME Making CAR-T Therapy Affordable While CAR-T therapies may well constitute the frontrunners in an amazing fresh wave of cell-based biomedical innovation that opens the door to truly individualized medicine, doubts continue to linger about their overall affordability…
BACK TO HOME Cell & Gene Therapy BACK TO HOME The Scalability and Manufacturing Barrier Long playing second fiddle to R&D and considered to be the more mundane segment of the pharma value chain, manufacturing has abruptly been thrust into the limelight when it comes to taking…
BACK TO HOME Cell & Gene Therapy BACK TO HOME The Power of Cell & Gene Cell and gene therapies are fast emerging as one of the most prospective and keenly anticipated areas of biologic medicine. Their buzz can be attributed both to the immense promise that…
HOMEPAGE Cell & Gene Therapy Cell and gene therapies are fast turning into a powerful engine of value creation for drugmakers and represent a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses. In the last five to ten years, for instance, we have…
See our Cookie Privacy Policy Here
